Anuh Pharma share price, P/E, ROE & financials

Anuh Pharma (ANUHPHR) had a P/E of 18.5× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 18% below their 52-week high. It earns ROCE of 15% and ROE of 14%, and sales and net profit grew 14% and 4.3% a year over 3 years. It has almost no debt, and its dividend yield is 1.8%. It is a small-cap company with a market cap of ₹817 Cr, ranked 74th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 6.8% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹83.92
Day high: ₹83.94
Day low: ₹81.00
Prev. close: ₹82.16
Volume: 59.5K

Health check

2 good · 3 fair · 1 to check

ReturnsBehind
−6.8% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 18.5 vs industry 28.7.
GrowthSteady
Sales +13.5%, profit +4.3% a year over 3 years.
ProfitabilityAverage
ROCE 15.4% vs peer median 17.9%.
Balance sheetFair
Debt 0.05× equity, interest covered 115.8×, Piotroski 5 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹817 Cr, #74 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹778 Cr · profit ₹48 Cr

Market cap: ₹817 Cr; Small cap
P/E: 18.5; Industry 28.7
Price to book: 2.27; Peers 4.99
Dividend yield: 1.83%
ROE: 13.9%; Peers 14.7%
ROCE: 15.4%; Peers 17.9%
Debt to equity: 0.05; Debt ₹19 Cr
EPS (TTM): ₹4.41; Face value ₹5
OPM (TTM): 8.3%; Net margin 6.1%
Sales growth: +3.9%; Latest quarter vs a year ago
Profit growth: +37.6%; Latest quarter vs a year ago
Price to sales: 1.05; EV/EBITDA 9.5

Strengths

Practically debt-free.
Quarterly profit up 37.6% on a year ago.
P/E of 18.5 against an industry P/E of 28.7.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Anuh Pharma

Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-hypertension, expectorant, anti-diabetics, anti-bacterial, anti-gout, anti asthmatics, quinolones, anti biotic, anti platelet, anti-histamines, and intermediates; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, and anti-mitotic. The…

Headquarters: Mumbai
Employees: 323
Sector: Healthcare
ISIN: INE489G01022
Website: anuhpharma.com

Price range

52 weeks

₹67.00₹99.50

Today

₹81.00₹83.94

Avg volume (3M): 1.6 L
1-year return: minus 6.8%
From 52-week high: minus 18.0%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.87%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.30%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.81%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.59%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.93%	minus 6.6%
ANUHPHRAnuh Pharma	81.55	minus 0.74%	817	18.5	2.27	15.4%	13.9%	8.3%	13.5%	4.3%	1.83%	minus 6.8%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.59%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
186	186	197	202	194
176	174	180	182	178
10.3	11.9	16.8	19.9	16.3
5.5%	6.4%	8.5%	9.8%	8.4%
3.4	1	4.1	0.6	1.2
0.2	0.1	0.1	0.1	0
2.5	2.9	3	3	2.4
–	–	–	−1.9	1.9
11	9.9	17.8	15.5	16.9
24.2%	23.3%	24.6%	24.7%	32.5%
8.3	7.6	13.5	11.7	11.4
1.66	0.76	1.34	1.17	1.14

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +13.5%
Profit CAGR 3Y: +4.3%
EPS CAGR 3Y: +4.3%
ROE: 13.9%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
527	647	662	772
–	+22.7%	+2.2%	+16.7%
473	571	596	703
54.1	76.3	65.6	68.3
10.3%	11.8%	9.9%	8.9%
−1.1	0.5	−1.8	−5.9
0.2	0.4	0.6	0.5
9.7	8.6	8.7	11.4
4.4	10.5	6.6	3.7
47.5	78.3	61	54.2
23.8%	23.3%	22.4%	24.3%
36.2	60.1	47.4	41
–	+66.0%	minus 21.2%	minus 13.3%
3.61	5.99	2.36	4.10

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
25.1	25.1	25.1	50.1
216	266	301	302
0.9	2.7	10.9	0.1
163	152	170	205
405	446	507	557
53.3	49.2	60.4	56.1
0.6	0.5	2.3	0.1
39.7	51.7	62	39.6
53.1	62.3	73.4	52.9
258	282	309	409
405	446	507	557

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
53.9	12.9	37.1	−3
−43.5	0.9	−19.9	17.8
−12.3	−8.6	−4.9	−26.3
−1.9	5.3	12.4	−11.5
−1.6	−5	−20.1	−7.9
52.4	7.9	17	−10.9
−8.7	−10	−12.5	−15

Shareholding pattern

Source: NSE filings

71.8%

promoters

Promoters71.80%
Public28.20%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	71.80%	28.20%	0.00
30 Jun 2026	71.80%	28.20%	0.00
31 Mar 2026	71.80%	28.20%	minus 0.02
31 Dec 2025	71.82%	28.18%	0.00
30 Sep 2025	71.82%	28.18%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you